Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

169973

registered interest
date	11/12/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Kidney Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many patients in England with advanced renal cell carcinoma have accessed treatment through the Cancer Drug Fund since April 2013.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	218434
answer	answer is ministerial correction date of answer 16/12/2014 answer text <p>NHS England has advised that it does not hold this information centrally.</p><p> </p><p> </p><p> </p><p>Between April 2013 and 30 September 2014, there have been 1,227 requests for drugs for advanced renal cell carcinoma through the Cancer Drugs Fund. However, actual uptake of treatment is dependent on variables which are unique to the patient’s individual clinical circumstances, the progression of the disease and the patient’s own choices.</p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 16/12/2014 17:26:39 answering member 4020 label Biography information for George Freeman
tabling member	1538 label Biography information for Rosie Cooper

169995

registered interest
date	11/12/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Kidney Cancer: Scotland
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, with reference to the approval by the Scottish Medicines Consortium of two second line treatments for renal cell carcinoma, if he will direct the Cancer Drug Fund panel to ensure that patients in England will continue to have access to treatments that are available on the NHS in Scotland for that condition.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	218530
answer	answer is ministerial correction date of answer 16/12/2014 answer text <p>We have no plans to do so. Decisions on which drugs are made available through the Cancer Drugs Fund are for NHS England’s Cancer Drugs Fund panel, in accordance with the Standard Operating Procedures for the Fund.</p><p> </p><p> </p><p> </p><p>There are two drugs for the second-line treatment of renal cell carcinoma – Afinitor (everolimus) and Inlyta (axitinib) - currently available through the Fund.</p><p> </p><p> </p><p> </p><p>Inlyta is also being appraised for this condition by the National Institute for Health and Care Excellence and final draft guidance recommending its use was published on 16 December 2014.</p><p> </p><p> </p><p> </p><p>NHS England has assured the Department that no patient whose treatment is currently being funded through the Cancer Drugs Fund will have funding withdrawn, as long as it is clinically appropriate that they continue to receive that treatment. In addition, no drug will be removed from the Fund where it is the only therapy for that condition.</p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 16/12/2014 17:23:20 answering member 4020 label Biography information for George Freeman
tabling member	1538 label Biography information for Rosie Cooper

169998

registered interest
date	11/12/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer Drugs Fund
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what factors will be considered in decisions as to which drugs are delisted from the Cancer Drug Fund.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	218528
answer	answer is ministerial correction date of answer 16/12/2014 answer text <p>The factors that will be taken into account by NHS England’s Cancer Drugs Fund panel are detailed at paragraph 6.7 of the Standard Operating Procedures for the Fund which is available at:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/ourwork/pe/cdf/" target="_blank">www.england.nhs.uk/ourwork/pe/cdf/</a></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 16/12/2014 16:58:54 answering member 4020 label Biography information for George Freeman
tabling member	1538 label Biography information for Rosie Cooper